ArticlePloS one2025
A research protocol using ECG monitoring for detection of palpitations-associated arrhythmias in breast cancer survivors.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Palpitations are common but understudied in breast cancer survivors (BCS). Palpitations may relate to severe arrhythmias, resulting in life-threatening events or cardiac death. However, how palpitations relate to arrhythmias and electrocardiogram abnormalities is unknown. The purpose of the proposed project is to demonstrate the feasibility of using wearable electrocardiogram (ECG) monitors in BCS to detect and characterize arrhythmias associated with self-reported palpitations and to gain a comprehensive understanding of palpitations using an investigator-designed Palpitations Assessment Tool (PAT). We will conduct a prospective cohort study of 84 BCS (54 BCS with palpitations and 30 without). Eligible participants will include breast cancer patients who completed chemotherapy at least six months ago and no more than three years ago. Palpitations and arrhythmias will be recorded using an ECG monitor for two 7-day periods, one month apart. Feasibility, acceptability, and retention, as measured by completion of the PAT and monitored wearing for 7 days, will be evaluated using frequency distribution in recruitment and retention logs. We will generate descriptive summaries of the prevalence of primary outcomes, including frequency of palpitations and changes in cardiac rate and rhythm, and examine associations between these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.